Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
431 Leser
Artikel bewerten:
(2)

Simpluris Inc.: If you purchased or acquired GYEN in New York or California at a time when it was unpegged from the Japanese Yen and lost money thereby, you may be entitled to a payment from a class action settlement.

COSTA MESA, Calif., Feb. 9, 2026 /PRNewswire/ -- The following statement is being issued by Simpluris, Inc., court-appointed settlement administrator, regarding the GYEN class action Settlement.

A proposed settlement has been reached with GMO-Z.com Trust Company ("Defendant" or "GMO Trust") in a class action lawsuit. The lawsuit alleges that GMO Trust violated New York and California law by failing to provide accurate disclosure concerning the stability of GYEN during the Settlement Class Period.

Defendant denies that it did anything wrong, and the Court has not decided who is right. The parties agreed to settle the lawsuit to avoid the risks, disruption, and uncertainties of continued litigation.

This press release is a supplement to, and does not replace, the Court-approved Long Form Notice. A copy of the proposed Settlement Agreement, the Long Form Notice, and other important information is available at www.GYENSettlement.com.

Settlement Class
The proposed Settlement Class consists of persons and entities that purchased or acquired GYEN in New York or California at a time when it was unpegged from the Japanese Yen between December 29, 2020 and October 10, 2025. Further, details about the Settlement Class definition can be found at www.GYENSettlement.com.

The Court has appointed experienced attorneys, known as Class Counsel, to represent the Settlement Class.

Settlement Benefits
If the Court approves the Settlement, Defendant will create a $6,750,000 Settlement Fund. Certain deductions, including attorneys' fees, litigation expenses, and the costs of notice and administration, will be paid from the Settlement Fund. The remaining money will be distributed among members of the Settlement Class Members in accordance with a plan of allocation approved by the Court.

Claims Process
To seek a payment, a claim must be submitted through the Settlement Website or submitted by U.S. mail using the Claim Form that is available for download at www.GYENSettlement.com, along with the required supporting documentation.

Claimants should be prepared to use the wallet connector included in the claim submission process to verify ownership or control of the wallet or account associated with the relevant GYEN transactions.

Paper Claim Forms may also be requested by emailing info@GYENSettlement.com or downloaded from the Settlement Website. Completed claims must be submitted online, mailed and postmarked, or emailed by June 5, 2026.

Exclusions and Objections
Requests for exclusion from the Settlement must be received by April 30, 2026. Persons or entities that exclude themselves will not be bound by the Settlement and will not be eligible to receive benefits.

Objections to the Settlement must be filed with the Court and served on counsel for the Settling Parties by April 30, 2026. You cannot object to any aspect of the Settlement if you exclude yourself from the Settlement Class.

Instructions for requesting exclusion or objecting to the Settlement are detailed in the Long Form Notice, which is available on the Settlement Website, www.GYENSettlement.com.

Final Approval Hearing
The Court will hold a hearing in this case at 2:00 p.m. on May 27, 2026, in Courtroom 11C of the Daniel Patrick Moynihan United States Courthouse, 500 Pearl Street, New York, NY 10007, to consider whether to approve the Settlement and plan of allocation. At that time, the Court will also consider Class Counsel's request for attorneys' fees, reimbursement of litigation expenses, and service awards for the named plaintiffs. Attendance at the hearing is not required.

This notice is a summary only and does not replace the Court-approved Long Form Notice. Additional information is available by calling 833-647-9041, emailing info@GYENSettlement.com, or visiting www.GYENSettlement.com.

Cision View original content:https://www.prnewswire.co.uk/news-releases/if-you-purchased-or-acquired-gyen-in-new-york-or-california-at-a-time-when-it-was-unpegged-from-the-japanese-yen-and-lost-money-thereby-you-may-be-entitled-to-a-payment-from-a-class-action-settlement-302682212.html

© 2026 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.